4basebio UK Societas (GB:4BB)
LSE:4BB
Want to see GB:4BB full AI Analyst Report?
Top Page
4basebio UK Societas
(LSE:4BB)
Select Model
Select Model
Rating:43Neutral
Price Target:
468.00 p
▼(-23.90% Downside)
Action:Reiterated
Date:05/22/26
The score is driven primarily by weak financial performance: persistent losses, accelerating cash burn, and a deteriorating capital structure (higher debt and lower equity). Technicals also lean negative with the stock below key longer-term moving averages and a negative MACD, while valuation offers limited support due to negative earnings and no dividend yield data.
Positive Factors
Strategic niche in gene therapy supply
4basebio supplies critical starting materials for viral vector and mRNA workflows, a structural input for gene therapies and advanced medicines. That product focus creates durable addressable demand as programs advance from R&D to clinical/commercial stages and supports long-term supply relationship potential.
Negative Factors
Persistent unprofitability
Sustained negative operating and net margins reflect structural profitability weakness: operating costs consistently overwhelm gross profit. Continued losses increase financing needs, dilute equity, and mean profitability depends on sustained revenue scale or significant cost base restructuring to be durable.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic niche in gene therapy supply
4basebio supplies critical starting materials for viral vector and mRNA workflows, a structural input for gene therapies and advanced medicines. That product focus creates durable addressable demand as programs advance from R&D to clinical/commercial stages and supports long-term supply relationship potential.
Read all positive factors
4basebio UK Societas (4BB) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£81.68M
Dividend YieldN/A
Average Volume (3M)999.00
Price to Earnings (P/E)―
Beta (1Y)-0.28
Revenue Growth81.46%
EPS Growth-15.88%
CountryUK
Employees101
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.09
Shares Outstanding15,538,518
10 Day Avg. Volume230
30 Day Avg. Volume999
Financial Highlights & Ratios
PEG Ratio-0.35
Price to Book (P/B)9.43
Price to Sales (P/S)56.33
P/FCF Ratio-6.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1
Revenue Forecast (FY)£2.60M
4basebio UK Societas Business Overview & Revenue Model
Company Description
4basebio PLC engages in the design, development, manufacturing, and supply of synthetic DNA and RNA products, and targeted non-viral vector solutions in the United States, Europe, and internationally. The company provides research kits, bulk enzym...
How the Company Makes Money
4basebio makes money primarily by supplying DNA starting materials and related services to biopharma and advanced-therapy developers.
Key revenue streams include:
1) Sale of DNA products (primarily plasmid DNA): The company generates revenue by p...
4basebio UK Societas Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.69M | 933.00K | 506.00K | 268.00K | 338.00K |
| Gross Profit | 548.00K | 630.00K | 340.00K | 239.00K | 269.00K |
| EBITDA | -15.58M | -10.97M | -7.34M | -5.41M | -3.21M |
| Net Income | -16.91M | -12.33M | -7.67M | -5.15M | -3.23M |
Balance Sheet | |||||
| Total Assets | 29.55M | 44.73M | 11.92M | 11.69M | 14.70M |
| Cash, Cash Equivalents and Short-Term Investments | 17.80M | 34.60M | 3.07M | 4.35M | 9.59M |
| Total Debt | 16.50M | 15.22M | 10.46M | 3.35M | 1.76M |
| Total Liabilities | 19.44M | 18.35M | 12.41M | 4.57M | 3.01M |
| Stockholders Equity | 10.11M | 26.38M | -492.00K | 7.12M | 11.70M |
Cash Flow | |||||
| Free Cash Flow | -15.21M | -12.31M | -7.67M | -6.64M | -4.25M |
| Operating Cash Flow | -14.75M | -10.74M | -6.18M | -4.70M | -2.74M |
| Investing Cash Flow | -1.64M | -1.57M | -1.49M | -1.94M | -1.51M |
| Financing Cash Flow | -369.00K | 43.87M | 6.42M | 1.24M | -467.00K |
4basebio UK Societas Technical Analysis
Positive
615.00
Price Trends
491.47
Positive
527.97
Negative
644.75
Negative
Market Momentum
1.57
Negative
70.99
Negative
77.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:4BB, the sentiment is Positive. The current price of 615 is above the 20-day moving average (MA) of 471.07, above the 50-day MA of 491.47, and below the 200-day MA of 644.75, indicating a neutral trend. The MACD of 1.57 indicates Negative momentum. The RSI at 70.99 is Negative, neither overbought nor oversold. The STOCH value of 77.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:4BB.
4basebio UK Societas Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | £87.52M | 11.77 | 65.83% | 8.33% | -8.21% | -5.27% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | £345.55M | -8.99 | -2929.47% | ― | ― | ― | |
44 Neutral | £15.94M | -9.84 | -210.32% | ― | -11.43% | 23.40% | |
43 Neutral | £81.68M | -4.85 | -116.21% | ― | 81.46% | -15.88% | |
40 Underperform | £7.94M | -0.19 | -316.67% | ― | 72.17% | 79.03% | |
40 Underperform | £19.00M | -5.88 | -213.66% | ― | 13.42% | 65.63% |
* Healthcare Sector Average
GB:4BB
4basebio UK Societas
527.50
-582.50
-52.48%
GB:AVCT
Avacta Group plc
79.00
42.00
113.51%
GB:BVXP
Bioventix
1,675.00
-1,015.22
-37.74%
GB:OBD
Oxford BioDynamics
0.19
-0.27
-58.89%
GB:FAB
Fusion Antibodies Plc
12.75
6.50
104.00%
GB:APTA
Aptamer Group Plc
0.55
0.21
61.76%
4basebio UK Societas Corporate Events
Regulatory Filings and Compliance
4basebio CEO Increases Stake with Market Purchase of Ordinary Shares
Positive
May 22, 2026
4basebio PLC, a Cambridge-based biotechnology company specialising in enzymatically produced synthetic DNA and mRNA for genetic medicines, serves developers of gene therapies, genome editing tools, mRNA products and DNA vaccines with tailored, GMP...
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and FinancingRegulatory Filings and Compliance
4basebio ramps up commercial push as revenue surges and GMP wins fuel synthetic DNA growth
Positive
May 20, 2026
4basebio reported an 81% increase in revenue to £1.7 million for 2025, driven by doubling DNA sales and growing contributions from clinical-stage projects, while posting a £16.9 million loss as it continued heavy investment in commercial...
Business Operations and StrategyFinancial Disclosures
4basebio Secures Seven-Figure Clinical Supply Deal for Phase II Immunotherapy Trial
Positive
May 20, 2026
4basebio PLC has signed a clinical supply agreement with a leading cancer immunotherapy developer to provide GMP-grade synthetic opDNA starting material for a Phase II trial. The deal underscores the company’s role as a key supplier of criti...
Business Operations and StrategyExecutive/Board Changes
4basebio strengthens leadership with new CFO and board reshuffle
Positive
May 14, 2026
4basebio PLC has appointed industry veteran Richard Bungay as Chief Financial Officer, effective July 2026, completing the build-out of its senior leadership team as it enters a phase of accelerated commercial growth. Bungay brings more than 30 ye...
Business Operations and Strategy
4basebio Leases New Cambridge Facility to Scale Synthetic DNA Manufacturing
Positive
Mar 31, 2026
4basebio has leased a new innovation hub and manufacturing facility at 31-35 Saxon Way in Bar Hill, near Cambridge, to expand production of research and high-quality synthetic DNA used in gene and cell therapies, mRNA vaccines, genome editing, and...
Business Operations and StrategyExecutive/Board Changes
4basebio Appoints COO to Drive Synthetic DNA Scale-Up and Commercial Growth
Positive
Mar 12, 2026
4basebio has appointed industry veteran Scott Lorimer as Chief Operating Officer to support its accelerated growth strategy and transition from an RD-focused organisation to a commercially scaled biomanufacturer. With over 30 years’ experien...
Business Operations and StrategyExecutive/Board Changes
4basebio bolsters commercial leadership to drive synthetic DNA growth
Positive
Mar 3, 2026
4basebio has strengthened its commercial leadership by promoting Christine Wolosin, a veteran life sciences executive with more than 25 years’ experience, to Chief Commercial Officer as the company enters an accelerated commercial phase. Wol...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.